In samples without 1p/19q co-deletion (Figures 1E, F), without MGMT promoter methylation (Figures 1G, H), and in IDH wild-type glioma patients (Figures 1I, J), we also found that patients had higher SIGLEC7 levels compared to the control group. This evidence concerns the gene MGMT and glioma.